Answers are grounded in this paper and cite their sources.
The objective of this economic evaluation was to compare two alternative therapeutic regimens for the treatment of type 2 diabetes: basal-bolus insulin vs basal insulin and DPP-4. We conducted a Cost-Minimization Analysis (CMA) to compare the annual cost of basal-bolus insulin regimen vs basal insulin and DPP-4 regimen from the perspective of the Italian National Health Service (NHS). The CMA considered only direct medical costs (basal insulin, bolus insulin and DPP-4 [sitagliptin] and self-monitoring of glycemic control). Costs were assessed in 2014 Euros. Sensitivity analysis and threshold analysis on key economic parameters were performed. The expected annual cost (per patient) was €987.60 with basal insulin and DPP-4 and €1,568.23 with basal-bolus insulin. As a consequence of a significant reduction of glycemic control costs, the regimen with DPP-4 was a cost-saving alternative from the perspective of the Italian NHS.
No takes yet. Share an insight, caveat, or question.
Roberto Ravasio (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: